Managed Healthcare Executive October 3, 2023
ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.
Now that a U.S. judge has rejected pharmaceutical companies’ arguments against Medicare price negotiations, all companies have indicated that they intend to participate in the program.
“Our goal is to ensure access to innovative treatments and therapies for people that need them when they need them. Medicare will negotiate in good faith consistent with the requirements of the law on behalf of people with Medicare,” Chiquita Brooks-LaSure, administrator of the Center for Medicare and Medicaid Services, said in a press release.
CMS released the list in August 2023 of the first 10 drugs to be...
Today's Sponsors
Today's Sponsor